Intensive CareNCT02924844
Impact of the Implementation of a Clinical Pharmacy Bundle on Intensive Care Unit Patient Outcomes and Cost Expenditures
An observational study of Intensive Care, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
Trial summary
The aim of this before-after study was to assess the impact of a clinical pharmacy bundle of care activities on patient outcomes (length of hospital stay as a primary endpoint) and cost expenditure in two French ICUs. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Intensive Care
- How many people
- 2,787 participants
- Where
- 1 siteFrance
- Study dates
- Jan 2013to Jun 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The two study populations are composed of all patients present in the ICU on weekdays. The first population is composed of patients present between January 2013 and December 2013. The second population is composed of patients present between January 2014 and June 2015.
Who may be able to join
- Intensive Care Unit patients on weekdays
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
The aim of this before-after study was to assess the impact of a clinical pharmacy bundle of care activities on patient outcomes (length of hospital stay as a primary endpoint) and cost expenditure in two French ICUs.
- Conditions
- Intensive Care
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Observation period before presence of clinical pharmacist | The group of patients was observed between Janary 2013 and December 2013 | |
| Period with presence of clinical pharmacist | The group of patients was observed between January 2014 and June 2015. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Length of hospital stay
Measured: expected average of 20 days
Secondary outcomes (5)
Intensive Care Unit length of stay
Measured: Expected maximum of 10 days
Mechanical ventilation duration
Measured: Expected maximum of 10 days
Intensive care unit mortality rate
Measured: Expected maximum of 10 days
Hospital mortality rate
Measured: End of hospital stay (expected average of 20 days)
Patient cost expenditure
Measured: End of hospital stay (expected average of 20 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Oct 2016 (estimated)
- Study startJan 2013
- Primary completionJun 2015
- Study completionJun 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intensive CareStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NīmesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 2,787 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02924844
- Sponsor's protocol ID
- IRB 14/05.03
- Status last verified
- Oct 2016
- First submitted
- 4 Oct 2016
- Last updated
- 18 Jun 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of the Implementation of a Clinical Pharmacy Bundle on Intensive Care Unit Patient Outcomes and Cost Expenditures
- ClinicalTrials.gov ID
- NCT02924844
- Acronym / sponsor ID
- IRB 14/05.03
- Conditions
- Intensive Care
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,787 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire de NīmesUniversity, hospital or other
- Study start
- Jan 2013
- Primary completion
- Jun 2015 (actual)
- Study completion
- Jun 2015 (actual)
- First posted
- 5 Oct 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this before-after study was to assess the impact of a clinical pharmacy bundle of care activities on patient outcomes (length of hospital stay as a primary endpoint) and cost expenditure in two French ICUs.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Observation period before presence of clinical pharmacist | – | –The group of patients was observed between Janary 2013 and December 2013 |
| Period with presence of clinical pharmacist | – | –The group of patients was observed between January 2014 and June 2015. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The two study populations are composed of all patients present in the ICU on weekdays. The first population is composed of patients present between January 2013 and December 2013. The second population is composed of patients present between January 2014 and June 2015.
Key inclusion criteria (1 listed)
- Intensive Care Unit patients on weekdays
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Length of hospital stay
Time frame: expected average of 20 days
5 secondary outcomes
Intensive Care Unit length of stay
Time frame: Expected maximum of 10 days
Mechanical ventilation duration
Time frame: Expected maximum of 10 days
Intensive care unit mortality rate
Time frame: Expected maximum of 10 days
Hospital mortality rate
Time frame: End of hospital stay (expected average of 20 days)
Patient cost expenditure
Time frame: End of hospital stay (expected average of 20 days)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2026.
Related trials for Intensive Care
Recruiting
Effect of Rutin and Vitamin C on Outcomes in Adults With Sepsis Admitted to the Intensive Care Unit
Sepsis
Not yet recruitingObservational study
CAROTID DOPPLER AND CEREBRAL OXIMERY IN POST CARDIAC ARREST ICU PATIENTS
Cardiac Arrest (CA), Carotid Doppler
Active, not recruitingObservational study
Potential Impact of the Use of the Application VentilO
Mechanical Ventilation Complication
Not yet recruitingPhase 4
Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 3
Canadian Critical Care Comparative Effectiveness Platform
Intensive Care Unit ICU, Vasopressor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Intensive Care, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Length of hospital stay (time frame: expected average of 20 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2026.